<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20220216054035N2</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-05</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>The effects of active and passive mobilization of tibial nerve in neuropathy of type 2 diabetic patients</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effects of active and passive mobilization of tibial nerve on pain intensity and conduction velocity of tibial nerve in neuropathy of type 2 diabetic patients</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-09-03</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>https://irct.ir/trial/80725</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Using the simple individual randomization method, patients who meet the study entry criteria after evaluation randomly select one of two types of sealed envelopes, corresponding to the active or passive mobilization method, and thus their type of intervention group is determined, Blinding description: Participants are unaware of which treatment group they will be placed in.
Participants in two different groups will be treated at different times so that they do not realize the differences in the treatments through observation and conversation with each other.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Neuropathy of diabetes.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Active mobilization of tibial nerve is performed five sessions per week for 3 weeks in supervised manner. To perform the neurodynamic gliding exercise of the tibial nerve: The patient sits in a slump position. In the starting position, the neck, trunk, and knee are in flexion, the ankle is in plantar flexion and inversion, that  brings the neck, trunk, and knee into extension and the ankle into dorsiflexion and eversion. This cycle lasts 4 seconds each time and we ask the patient to repeat this 10 times sitting on the bed. Intervention 2: Intervention group 2: passive mobilization of tibial nerve with the patient in the supine position five sessions per week for 3 weeks. Tibial nerve glide The patient is in the supine position, in the starting position the patient's knee is in extension and the ankle is in plantarflexion and inversion, and the therapist moves the ankle to dorsiflexion and eversion and the knee to flexion.Tibial nerve tension with the shock lock method: The patient is in the supine position, in the starting position the patient's knee is in flexion and the ankle is in plantarflexion and inversion, and the therapist moves the ankle to dorsiflexion and eversion and the knee to extension. This method is performed 10 times for the patient in each session.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Pain intensity

When:
Six months after publication of the paper

To whom:
All people

Conditions:
People that research in this field

Where to obtain:
Via email:
monireaalem@gmail.com

How to obtain:
Send a request via email and state for what purpose he/she need the data.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Monire Alem</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Rehabilitation Sciences, Shahid Beheshti University of Medical Sciences, in front of Bu Ali hospital, Damavand Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985713871</zip>
        <telephone>+98 21 7754 2057</telephone>
        <email>monireaalem@gmail.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Seyyed Majid Hossaini</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Faculty of Rehabilitation Sciences, Shahid Beheshti University of Medical Sciences, in front of Bu Ali hospital, Damavand Street</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1985713871</zip>
        <telephone>+98 21 7754 2057</telephone>
        <email>majidhosseini44@yahoo.com</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Passing at least 2 years since the onset of diabetes
Their leg pain is 3 or higher
Their blood sugar levels are in the range of 100-250
It has been 6 months since the onset of neuropathy symptoms
Men and women with type 2 diabetes
In the age group of 40-75 years
Grade 1 and 2 neuropathy via monofilament instrument, Michigan questionnaire, and tibial nerve conduction velocity assessment</inclusion_criteria>
      <agemin>40 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diabetic foot ulcer
Irritable pain
Lumbar disc herniation
Damage to the nerves of the lower extremities
History of cardiovascular disease
Musculoskeletal deformity
Lack of cooperation or understanding during sensory testing or manual therapy
Dependency to drug or alcohol
Lumbar disc herniation
Damage to the nerves of the lower extremities
Retinopathy
History of cardiovascular disease</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E11.40</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Type 2 diabetes mellitus with diabetic neuropathy, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Active mobilization of tibial nerve is performed five sessions per week for 3 weeks in supervised manner. To perform the neurodynamic gliding exercise of the tibial nerve: The patient sits in a slump position. In the starting position, the neck, trunk, and knee are in flexion, the ankle is in plantar flexion and inversion, that  brings the neck, trunk, and knee into extension and the ankle into dorsiflexion and eversion. This cycle lasts 4 seconds each time and we ask the patient to repeat this 10 times sitting on the bed.</i_keyword>
      <i_keyword>Intervention group 2: passive mobilization of tibial nerve with the patient in the supine position five sessions per week for 3 weeks. Tibial nerve glide The patient is in the supine position, in the starting position the patient's knee is in extension and the ankle is in plantarflexion and inversion, and the therapist moves the ankle to dorsiflexion and eversion and the knee to flexion.Tibial nerve tension with the shock lock method: The patient is in the supine position, in the starting position the patient's knee is in flexion and the ankle is in plantarflexion and inversion, and the therapist moves the ankle to dorsiflexion and eversion and the knee to extension. This method is performed 10 times for the patient in each session.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Conduction velocity of tibial nerve. Timepoint: Before intervention and end of treatment sessions (19th day). Method of measurement: Electromyography.</prim_outcome>
      <prim_outcome>Pain. Timepoint: Before intervention and end of treatment sessions (19th day). Method of measurement: Visual analog scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Neuropathy score on the Michigan Questionnaire. Timepoint: Before intervention and end of treatment sessions (19th day). Method of measurement: With Michigan questionnaire,  this questionnaire consists of two parts: Part A,ranging from 0 to a score of 13, with a higher score indicating greater severity of neuropathy , and Part B, where a score above 2 indicates neuropathy.</sec_outcome>
      <sec_outcome>Quality of life questionnaire score. Timepoint: Before intervention and end of treatment sessions (19th day). Method of measurement: Quality of life  Questionnaire with 15 questions.</sec_outcome>
      <sec_outcome>Leg raising range of motion. Timepoint: Before intervention and end of treatment sessions (19th day). Method of measurement: Goniometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2024-12-14</approval_date>
        <contact_name>Ethics committee of Shahid Beheshti University of Medical Sciences</contact_name>
        <contact_address>No. 8, Shams Alley, before Tavanir, Valiasr Street, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
